Noradrenergic function in generalized anxiety disorder: Impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge

Journal of Psychopharmacology

Volumn 25, Issue 1, 2011, Pages 78-86

  Hood, S D ^a,b   Melichar, J K ^a   Taylor, L G ^a,d   Kalk, N ^a   Edwards, T R ^a   Hince, D A ^b   Lenox Smith, A ^c   Lingford Hughes, A R ^a   Nutt, D J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PFIZER INC   (United States)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

clonidine; generalized anxiety disorder; noradrenergic; physiological; psychological; saccadic eye movements; verbal fluency

Indexed keywords

CLONIDINE; GROWTH HORMONE; HYDROCORTISONE; VENLAFAXINE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ELECTROPHYSIOLOGY; FEMALE; HEART RATE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SACCADIC EYE MOVEMENT; SEDATION; TASK PERFORMANCE;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; ANXIETY DISORDERS; BLOOD PRESSURE; CLONIDINE; CYCLOHEXANOLS; EYE MOVEMENTS; FEMALE; HEART RATE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOREPINEPHRINE; RECEPTORS, ADRENERGIC; SEROTONIN UPTAKE INHIBITORS;

EID: 78650591720     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109359099     Document Type: Article

References (41)

1. Abelson JL, Glitz D., Cameron OG, Lee MA, Bronzo M., Curtis GC (1991) Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 48: 157-162.
2. Allgulander C., Hartford J., Russell J., et al. (2007) Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 23: 1245-1252.
3. Allgulander C., Nutt D., Detke M., et al. (2008) A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 22: 417-425.
4. American Psychiatric Association. (1994) Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: APA.
5. 2 results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology 27: 715-729.
6. Baldwin DS, Anderson IM, Nutt DJ, et al. (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19: 567-596.
7. Ball DM, Glue P., Wilson S., Nutt DJ (1991) Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil. Psychopharmacology (Berl) 105: 361-367.
8. Borkowski JG, Benton AL, Spreen O. (1967) Word fluency and brain damage. Neuropsychologia 5: 135-140.
9. Cella SG, Picotti GB, Muller EE (1983) alpha2-Adrenergic stimulation enhances growth hormone secretion in the dog: a presynaptic mechanism? Life Sci 32: 2785-2792.
10. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR (1992) Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 86: 273-282.
11. Girden ER (1992) ANOVA: Repeated Measures. Newbury Park, CA: Sage.
12. Giustina A., Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19: 717-797.
13. Glue P., Nutt D. (1988) Clonidine challenge testing of alpha-2-adrenoceptor function in man: the effects of mental illness and psychotropic medication. J Psychopharmacol 2: 119-137.
14. Glue P., White E., Wilson S., Ball DM, Nutt DJ (1991) Pharmacology of saccadic eye movements in man. 2. Effects of the alpha 2-adrenoceptor ligands idazoxan and clonidine. Psychopharmacology (Berl) 105: 368-373.
15. Gold MS, Redmond Jr DE, Kleber HD (1978) Clonidine in opiate withdrawal. Lancet 1: 929-930.
16. Guy W (ed.) (1976) ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. US Department of Health, Education, and Welfare, Washington, DC.
17. Hood SD, Hince DA, Robinson H., Cirillo M., Christmas D., Kaye JM (2006) Serotonin regulation of the human stress response. Psychoneuroendocrinology 31: 1087-1097.
18. Kalk NJ, Nutt DJ, Lingford-Hughes AR The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies (submitted).
19. Khurana RN, Baudendistel TE (2003) Hypertensive crisis associated with venlafaxine. Am J Med 115: 676-677.
20. Lancranjan I., Marbach P. (1977) New evidence for growth hormone modulation by the alpha-adrenergic system in man. Metabolism 26: 1225-1230.
21. Marten PA, Brown TA, Barlow DH, Borkovec TD, Shear MK, Lydiard RB (1993) Evaluation of the ratings comprising the associated symptom criterion of DSM-III-R generalized anxiety disorder. J Nerv Ment Dis 181: 676-682.
22. Melichar JK, Haida A., Rhodes C., Reynolds AH, Nutt DJ, Malizia AL (2001) Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers. J Psychopharmacol 15: 9-12.
23. Miki N., Ono M., Shizume K. (1984) Evidence that opiatergic and alpha-adrenergic mechanisms stimulate rat growth hormone release via growth hormone-releasing factor (GRF). Endocrinology 114: 1950-1952.
24. Moffoot A., O'Carroll RE, Murray C., Dougall N., Ebmeier K., Goodwin GM (1994) Clonidine infusion increases uptake of 99mTc-Exametazime in anterior cingulate cortex in Korsakoff's psychosis. Psychol Med 24: 53-61.
25. Munoz DP, Broughton JR, Goldring JE, Armstrong IT (1998) Age-related performance of human subjects on saccadic eye movement tasks. Exp Brain Res 121: 391-400.
26. Nalepa I., Manier DH, Gillespie DD, Rossby SP, Schmidt DE, Sulser F. (1998) Lack of [beta] adrenoceptor desensitization in brain following the dual noradrenaline and serotonin reuptake inhibitor venlafaxine. Eur Neuropsychopharmacol 8: 227-232.
27. Nash JR, Wilson SJ, Potokar JP, Nutt DJ (2003) Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 61: 1161.
28. Nutt DJ (1986) Increased central alpha 2-adrenoceptor sensitivity in panic disorder. Psychopharmacology (Berl) 90: 268-269.
29. Nutt DJ (1989) Altered central alpha 2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry 46: 165-169.
30. Nutt DJ, Glue P. (1991) Imipramine in panic disorder. 2. Effects on {alpha}2-adrenoceptor function. J Psychopharmacol 5: 135-141.
31. Papakostas GI, Thase ME, Fava M., Nelson JC, Shelton RC (2007) Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 62: 1217-1227.
32. Posner MI, Petersen SE, Fox PT, Raichle ME (1988) Localization of cognitive operations in the human brain. Science 240: 1627-1631.
33. Rickels K., Pollack MH, Sheehan DV, Haskins JT (2000) Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157: 968-974.
34. Schittecatte M., Garcia-Valentin J., Charles G., et al. (1995) Efficacy of the 'clonidine REM suppression test (CREST)' to separate patients with major depression from controls; a comparison with three currently proposed biological markers of depression. J Affect Disord 33: 151-157.
35. Shedlack KJ, Hunter R., Wyper D., McLuskie R., Fink G., Goodwin GM (1991) The pattern of cerebral activity underlying verbal fluency shown by split-dose single photon emission tomography (SPET or SPECT) in normal volunteers. Psychol Med 21: 687-696.
36. Sheehan DV, Lecrubier Y., Sheehan KH, et al. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20). 22-33.
37. Smith A., Brice C., Nash J., Rich N., Nutt DJ (2003) Caffeine and central noradrenaline: effects on mood, cognitive performance, eye movements and cardiovascular function. J Psychopharmacol 17: 283-292.
38. Spielberger CD, Gorsuch RL, Lushene R., Vagg PR, Jacobs GA (1983) Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists' Press.
39. Thase ME (1998) Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 59: 502-508.
40. Tombaugh TN, Kozak J., Rees L. (1999) Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol 14: 167-177.
41. Uhde TW, Vittone BJ, Siever LJ, Kaye WH, Post RM (1986) Blunted growth hormone response to clonidine in panic disorder patients. Biol Psychiatry 21: 1081-1085.